Navigation Links
Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
Date:11/3/2010

SEATTLE, Nov. 3, 2010 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has been awarded non-taxable grants totaling approximately $1.7 million under the Qualifying Therapeutic Discovery Project (QTDP) included in the Patient Protection and Affordable Health Care Act of 2010.

To be eligible to receive a grant award under the QTDP program, projects must show reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute disease and conditions; to reduce long-term health care costs in the United States; or to significantly advance the goal of curing cancer within 30 years. Grant applications were reviewed by both the Treasury Department and the Department of Health and Human Services.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and cent
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
6. Omeros Appoints New Vice President of Clinical Development
7. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
8. Omeros Commences Initial Public Offering of Common Stock
9. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING, ... KOOL ), a leading supplier of innovative products ... said it has,received authorization from the FDA to begin ... laboratory setting or intraoperatively,for preparation of a cell concentrate ...
... water through point-of-use ... ultrafiltration, NEW ... device company, announced today that it will be exhibiting its,Dual Stage ... Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building on the ...
... July 14 Phlo Corporation,(Pink Sheets: PHCP) (the ... California of its vitality beverage, AQISS(TM),will be significantly ... of,the largest specialty beverage distributors in the San ... reached an agreement in principal with Morris,Distributing providing ...
Cached Biology Technology:ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 2ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 3ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 4Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Phlo Affiliate Announces Significant Distribution Expansion In California 2
(Date:9/15/2014)... in the Department of Science and Technology in Society ... at Virginia Tech, has won a 2014 National Science ... prospects and problems of creating a global nuclear emergency ... I Nuclear Power Plant in March 2011 was a ... emergencies, Schmid said. Three of the plant,s six nuclear ...
(Date:9/15/2014)... the oceans, there must be enough dissolved oxygen ... oxygen-starvation produces "dead zones" that decimate marine fisheries ... levels decline, energy is increasingly diverted away from ... impacts on the ecology and biogeochemistry of the ... minimum zones (OMZs) have expanded due to climate ...
(Date:9/15/2014)... and cognitive function may play roles in one,s musical ... pitch, timbre, tone durations, and formal structure in music. ... explain that extremes in musical aptitude (extreme capacity/no capacity) ... individuals having moderate aptitude. , "This is a typical ... genes, and it is influenced to varying degrees by ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... Established in 2007 and based in Toronto, ArcticDx has ... kind and specifically designed to determine one,s inherited risk ... of acquired blindness in the developed world, affecting over ... investment to undertake studies in support of a planned ...
... One of the many advantages of maintaining a normal body ... healthy heart. Fat tissue is increasingly seen as more than ... organ that normally produces high levels of a cardioprotective hormone ... has long been a mystery, and now a team led ...
... the Morrison Natural History Museum have again discovered infant ... near the town of Morrison. Dating from the Late ... made before the Rocky Mountains rose, when Morrison was ... tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, ...
Cached Biology News:OGI invests in personalized medicine for age-related macular degeneration 2Study finds fat hormone's long-sought link to heart protection 2Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: